EAM
BPMC

Exome Asset Management’s Blueprint Medicines BPMC Stock Holding History

Exome Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,800
Closed -$2.77M – 65
2024
Q4 		$2.77M Sell
31,800
-4,900
-13% -$449K 2.08% 20
2024
Q3 		$3.39M Buy
+36,700
New +$3.65M 2.29% 15

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Exome Asset Management's BPMC Position: Q1 2025 in Review

Exome Asset Management sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 31,800 shares — an estimated $2.77M sold.

Exome Asset Management first reported a position in BPMC in Q3 2024 and held it in 2 quarters. The position peaked at $3.39M in Q3 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Exome Asset Management reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 31,800 Blueprint Medicines shares in Q1 2025, an estimated $2.77M.
  • Exome Asset Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 2 quarters.
  • Exome Asset Management's Blueprint Medicines position peaked at $3.39M in Q3 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.